David Woodward

Dr. David Woodward


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1994 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
DWDavid Woodward
David Woodward
Moon Fai ChanMoon Fai Chan
Moon Fai Chan
JBJ.A. Burke
J.A. Burke
ACA. Cheng-Bennett
A. Cheng-Bennett
GCG. Chen
G. Chen
LWL.S. Williams
L.S. Williams
The use of natural prostaglandins (PG), such as PGD2, PGF2, PGF2α, and PGI2, for treating glaucoma is limited by their ocular side effects. One approach to achieve the required separation of ocular hypotensive activity from side effects is to employ ester prodrugs. From a novel series of 11- and 15-mono and 11,15-diacyl esters of PGF2α we identified prodrugs where PGF2α formation rates in the iris-ciliary body exceeded those in the conjunctiva, sciera, and corneal endothelium. Compared to PGF2α-1-isopropyl ester the ocular tissue hydrolysis rates of the 11-monopivaloyl, the 11,15-dipivaloyl ester and the 1,11-lactone were up to 1000 fold less. Despite this large disparity in hydrolysis rates, the pivaloyl esters and the 1,11-lactone were potent ocular hypotensives in our animal models. In studying prostaglandin analogs, we found that a diverse variety of prostanoid receptor selective agonists lowered intraocular pressure in dogs and/or monkeys. These included DP-, EP1-, EP2-, EP3-, and FP-receptor selective compounds. These findings were surprising and prompted us to re-examine the receptor selectivity of these agonists by radioligand binding studies. Using radiolabelled PGE2,17-phenyl PGF2α, and sulprostone we were able to confirm the selectivity of the agonists currently used for receptor characterization directly by radioligand binding competition studies. It appears that multiple prostanoid receptor subtypes may be involved in regulating intraocular pressure.

20 October 2018 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
RCR A Coleman
R A Coleman
AWA J Woodrooffe
A J Woodrooffe
KCK L Clark
K L Clark
CTC B Toris
C B Toris
SFS Fan
S Fan
DWDavid Woodward
David Woodward
Background and Purpose: Prostanoid EP 2 receptor agonists exhibit several activities including ocular hypotension, tocolysis and anti‐inflammatory activity. This report describes the affinity and selectivity of a structurally novel, non‐prostanoid EP 2 receptor agonist, PGN‐9856, and its therapeutic potential. Experimental Approach: The pharmacology of a series of non‐prostanoid EP 2 receptor agonists was determined according to functional and radioligand binding studies, mostly using human recombinant prostanoid receptor transfectants. The selectivity of PGN‐9856, as the preferred compound, was subsequently determined by using a diverse variety of non‐prostanoid target proteins. The therapeutic potential of PGN‐9856 was addressed by determining its activity in relevant primate cell, tissue and disease models. Key Results: PGN‐9856 was a selective and high affinity (pKi ≥ 8.3) ligand at human recombinant EP 2 receptors. In addition to high affinity binding, it was a potent and full EP 2 receptor agonist with a high level of selectivity at EP 1 , EP 3 , EP 4 , DP, FP, IP and TP receptors. In cells overexpressing human recombinant EP 2 receptors, PGN‐9856 displayed a potency (pEC 50 ≥ 8.5) and a maximal response (increase in cAMP) comparable to that of the endogenous agonist PGE 2 . PGN‐9856 exhibited no appreciable affinity (up 10 μM) for a range of 53 other receptors, ion channels and enzymes. Finally, PGN‐9856 exhibited tocolytic, anti‐inflammatory and long‐acting ocular hypotensive properties consistent with its potent EP 2 receptor agonist properties. Conclusions and Implications: PGN‐9856 is a potent, selective and efficacious prostanoid EP 2 receptor agonist with diverse potential therapeutic applications: tocolytic, anti‐inflammatory and notably anti‐glaucoma.

29 September 2015 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JWJenny W. Wang
Jenny W. Wang
DWDavid Woodward
David Woodward
JMJose L. Martos
Jose L. Martos
CCClive L. Cornell
Clive L. Cornell
RCRobert W. Carling
Robert W. Carling
LMLawrence J. Marnett
Lawrence J. Marnett
A polypharmacologic approach to prostanoid based anti‐inflammatory therapeutics was undertaken in order to exploit both the anti‐ and proinflammatory properties attributed to the various prostanoid receptors. Multitargeting of selected prostanoid receptors yielded a prototype compound, compound 1 (AGN 211377), that antagonizes prostaglandin D 2 receptors (DPs) DP 1 (49) and DP 2 (558), prostaglandin E 2 receptors (EPs) EP 1 (266) and EP 4 (117), prostaglandin receptor (FP) (61), and thromboxane A 2 receptor (TP) (11) while sparing EP 2 , EP 3 , and prostaglandin I 2 receptors (IPs); K b values (in nanomoles) are given in parentheses. Compound 1 evoked a pronounced inhibition of cytokine/chemokine secretion from lipopolysaccharide or TNF‐α stimulated primary human macrophages. These cytokine/chemokines included cluster of designation 40 receptor (CD40), epithelial‐derived neutrophil‐activating protein 78 (ENA‐78), granulocyte colony stimulating factor (G‐CSF), granulocyte macrophage colony stimulating factor (GM‐CSF), IL‐8, IL‐18, monocyte chemotactic protein‐1 (CCL2) (MCP‐1), tissue plasminogen activator inhibitor (PAI‐1), and regulated on activation, normal T cell expressed and secreted (RANTES). In contrast, the inhibitory effects of most antagonists selective for a single receptor were modest or absent, and selective EP 2 receptor blockade increased cytokine release in some instances. Compound 1 also showed clear superiority to the cyclooxygenase inhibitors diclofenac and rofecoxib. These findings reveal that blockade of multiple prostanoid receptors, with absent antagonism of EP 2 and IP, may provide more effective anti‐inflammatory activity than global suppression of prostanoid synthesis or highly selective prostanoid receptor blockade. These investigations demonstrate the first working example of prostanoid receptor polypharmacology for potentially safer and more effective anti‐inflammatory therapeutics by blocking multiple proinflammatory receptors while sparing those with antiinflammatory activity.—Wang, J. W., Woodward, D. F., Martos, J. L., Cornell, C. L., Carling, R. W., Kingsley, P. J., Marnett, L. J. Multitargeting of selected prostanoid receptors provides agents with enhanced anti‐inflammatory activity in macrophages. FASEB J. 30, 394‐404 (2016). www.fasebj.org

1 June 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
DFDeborah P. Fischer
Deborah P. Fischer
AGAnna L. Griffiths
Anna L. Griffiths
SLSylvia Lui
Sylvia Lui
USUzmah J. Sabar
Uzmah J. Sabar
DFDiane Farrar
Diane Farrar
KMKay M. Marshall
Kay M. Marshall
Prostaglandin (PG) E analogues are used clinically to ripen the cervix and induce labour. However, selective receptor agonists may have potential to improve induction response rates or manage unwanted uterine hypercontractility in conditions such as dysmenorrhoea and preterm labour. To characterise their therapeutic value, PGE2 analogues were used to investigate the functional EP receptor population in isolated human uterus. Responsiveness in mouse tissues was also examined to validate its use as a pre-clinical model. Uterine samples were obtained from mice at dioestrus (n=12), term gestation (n=14) and labour (n=12) and from the lower uterus of women undergoing hysterectomy (n=12) or Caesarean section (n=18). Vehicle and agonist effects were assessed using superfusion and immersion techniques. PGE2 evoked predominant excitatory responses in mouse and relaxation in human tissues. Selective EP4 agonists inhibited tissue activity in both non-pregnant species, whilst the EP2 mimetic CP533536 also attenuated uterine contractions throughout gestation. The uterotonic effects of the EP3/1 agonist sulprostone were more pronounced than the EP1 agonist ONO-D1-004, corresponding to abundant EP3 receptor expression in all samples. The contractile phenotype in mouse compared to human uteri may relate to regional differences as well as high expression of EP3 receptor transcripts. Similarities in non-pregnant and gestational tissues across species suggest that EP3 may represent a valuable translational drug target for preventing uterine hypercontractility by employing a selective antagonist. SIGNIFICANCE STATEMENT This research validates the use of non-pregnant mice for pre-clinical drug discovery of uterine EP receptor targets. To determine the utility of novel drugs and delivery systems at term pregnancy and labour, pharmacological agents interacting with EP3 receptors have clear translational value.

5 January 2021 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
JBJacques A Bertrand
Jacques A Bertrand
DWDavid Woodward
David Woodward
JSJoseph M Sherwood
Joseph M Sherwood
ASAlice Spenlehauer
Alice Spenlehauer
CSCristoforo Silvestri
Cristoforo Silvestri
DODarryl R Overby
Darryl R Overby

25 November 2020 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
JBJacques A Bertrand
Jacques A Bertrand
DWDavid Woodward
David Woodward
JBJoseph van Batenburg-Sherwood
Joseph van Batenburg-Sherwood
JWJenny W Wang
Jenny W Wang
DODarryl R Overby
Darryl R Overby
Background: A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP 2 receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP 2 receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP 2 receptors. Methods: The protracted IOP reduction produced by JV-GL1 was investigated in C57BL/6J and EP 2 receptor knock-out mice (B6.129- Ptger2 tm1Brey /J; EP 2 KO). Both ocular normotensive and steroid-induced ocular hypertensive (SI-OHT) mice were studied. IOP was measured tonometrically under general anaesthesia. Aqueous humour outflow facility was measured ex vivo using iPerfusion in normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days prior. Results: Both the initial 1-day and the protracted multiday effects of JV-GL1 in the SI-OHT model for glaucoma were abolished by deletion of the gene encoding the EP 2 receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP 2 KO mice, but in littermate SI-OHT EP 2 WT control mice, JV-GL1 statistically significantly lowered IOP for 4–6 days. Conclusions: Both the 1-day and the long-term effects of JV-GL1 on IOP are entirely EP 2 receptor dependent.